Resistance to Proteasome Inhibitors in Cancer / Resistance to Targeted Anti-Cancer Therapeutics (PDF)

Name: Resistance to Proteasome Inhibitors in Cancer / Resistance to Targeted Anti-Cancer Therapeutics
Brand: Springer-Verlag GmbH
SKU: 69872605
Price: 153.99 EUR
Availability: OnlineOnly

Molecular Mechanisms and Strategies to Overcome Resistance (Sprache: Englisch)

Schreiben Sie einen Kommentar zu "Resistance to Proteasome Inhibitors in Cancer / Resistance to Targeted Anti-Cancer Therapeutics".

Merken

Mehr zum Inhalt Autorenporträt Video

eBook (pdf) 153.99 €

Buch (Gebunden) 164.99 €

sofort als Download lieferbar

Bestellnummer: 69872605

Printausgabe 164.99 €

eBook (pdf) -7% 153.99 €

Download bestellen

Verschenken

Lastschrift, Kreditkarte, Paypal, Rechnung
Kostenloser tolino webreader

Produktdetails

Produktbeschreibung
Autorenporträt
eBook Hilfe
Biblio. Angaben / Produktdetails

Produktinformationen zu „Resistance to Proteasome Inhibitors in Cancer / Resistance to Targeted Anti-Cancer Therapeutics (PDF)“

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.¿

Autoren-Porträt

Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.